Table 5.

Topics reported as being "very important" or "quite important" for the National Ethics Committees (NECs).

Topics	Numbers of NECs reporting topic (%)
Monitoring and oversight	87% (13/15)
Assessment of understanding of informed consent	80% (12/15)
Privacy and confidentiality	80% (12/15)
Provision of appropriate risk reduction measures	80% (12/15)
Assessment of cultural sensitivity for informed consent	73% (11/15)
Placebo controlled trials	73% (11/15)
Determination of appropriate subject selection in vulnerable populations	67% (10/15)
Assessment of anticipated benefits	67% (10/15)
Community participation	67% (10/15)
Determinations to conduct Phase I, II, and III clinical trials in a country or community	60% (9/15)
Incentives for participation	60% (9/15)